ValiRx subsidiary Inaphaea signs deal with Agility Life Sciences

This AIM-traded firm said the partnership was designed to streamline and enhance the drug development process.

It said clients availing of Inaphaea's services would be able to directly benefit from Agility's capabilities without requiring a separate contract with Agility.

The same would hold true for Agility's clients, who would now have unobstructed access to Inaphaea's range of services.

ValiRx said one significant advantage of the partnership was the introduction of a unified point of contact for clients.

Instead of navigating multiple channels, service users would have a straightforward way to formulate and test their drug candidates, thanks to the joint capabilities of both Inaphaea and Agility.

The move would both simplify the drug development process, as well as accelerate the journey from research to market-ready solutions.

“We have appreciated the skills and creativity displayed by Agility during the two projects we have run with them, so we're delighted to be able to offer these capabilities to our service users, as well as to continue using these capabilities for our in-house programmes,” said chief executive officer Dr Suzy Dilly.

“In a comparative manner to our collaborative services agreement with Physiomics announced in April, this new arrangement with Agility further expands the Inaphaea service capability.

“This agreement is very much reciprocal, and we expect to be able to offer our services to Agility customers just as much as offering their services to ours.”

At 0916 BST, shares in ValiRx were up 3.65% at 7.1p.

Reporting by Josh White for Sharecast.com.